Fig. 4

CD73 deficiency on T cells is sufficient to improve anti-4-1BB therapy. B16-SIY tumor-bearing Rag1^−/− mice receiving WT or CD73^−/− pan-T cells were treated with control IgG or anti-4-1BB. a Tumor size was measured every 2–3 days. b Tumor weight was measured 14 days after tumor challenge. c Survival curves of these B16-SIY-bearing mice. d Percentage of CD4⁺ or CD8⁺ T cells among total CD45⁺ tumor infiltrates. e Percentage of CD45⁺ cells among total tumor infiltrates. f Percentage of Ki67⁺ in tumor-infiltrating CD8⁺ T cells and percentage of CD73⁺ in tumor-infiltrating CD4⁺ or CD8⁺ T cells were also determined. Percentage of CD8⁺IFN-γ⁺ (g) or CD4⁺Foxp3⁺ Tregs (h) among total CD45⁺ tumor infiltrates. i The ratio of CD8⁺IFN-γ⁺ to CD4⁺Foxp3⁺ Tregs was calculated in treated B16-SIY-bearing Rag1^−/− mice. j Percentage of CD73⁺ in tumor-infiltrating CD4⁺ or CD8⁺ T cells in treated B16-SIY-bearing Rag1^−/− mice. *p < 0.05, **p < 0.01. ANOVA analysis, log-rank test and unpaired Student’s two-tailed t test were used. Data (mean ± SEM) are representative of 2 independent experiments with 3–5 independently analyzed mice/group